These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 35856212)

  • 1. [Based on a Markov model, cost-effectiveness analysis of influenza vaccination among people aged 60 years and older in Shenzhen].
    Wu XL; Ye ZJ; Xie F; Huang DF; Kong TJ; Feng SX; Zhang YW; Jiang Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Jul; 43(7):1140-1146. PubMed ID: 35856212
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of dual influenza and pneumococcal vaccination among the elderly in Shenzhen, China.
    Chen D; Ye Z; Pi Z; Mizukami S; Aoyagi K; Jiang Y
    Vaccine; 2021 Apr; 39(16):2237-2245. PubMed ID: 33757667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza vaccination for heart failure patients: a cost-effectiveness analysis from the perspective of Chinese healthcare system.
    Zhao M; Liu F; Wang L; Chen D
    Front Public Health; 2024; 12():1348207. PubMed ID: 39185111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.
    Brydak L; Roiz J; Faivre P; Reygrobellet C
    Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effective analysis of seasonal influenza vaccine in elderly Chinese population].
    Chen C; Liu GE; Wang MJ; Gao TF; Jia HP; Yang H; Feng LZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):993-999. PubMed ID: 31607044
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimal timing of influenza vaccination in patients with human immunodeficiency virus: a Markov cohort model based on serial study participant hemoagglutination inhibition titers.
    Werker GR; Sharif B; Sun H; Cooper C; Bansback N; Anis AH
    Vaccine; 2014 Feb; 32(6):677-84. PubMed ID: 24355089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of seasonal influenza vaccination in WHO-defined high-risk populations in Bangladesh.
    Hassan MZ; Jubayer Biswas MAA; Shirin T; Rahman M; Chowdhury F; Azziz-Baumgartner E; Davis WW; Hussain M
    J Glob Health; 2024 Jul; 14():04126. PubMed ID: 39024624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cost-effectiveness analysis of quadrivalent influenza vaccination for older adults aged 60 and above in mainland China].
    Yan H; Yang J; Chen ZY; Gong H; Zhong GJ; Yu HJ
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2405-2412. PubMed ID: 34404135
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G; Gregg M; Poulsen Nautrup B
    J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Cost-Effectiveness of an Influenza Vaccination Program Offering Microneedle Patch for Vaccine Delivery in Children.
    Wong C; Jiang M; You JH
    PLoS One; 2016; 11(12):e0169030. PubMed ID: 28006012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.
    You JH; Wong WC; Ip M; Lee NL; Ho SC
    J Epidemiol Community Health; 2009 Nov; 63(11):906-11. PubMed ID: 19608558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of an influenza vaccination program offering intramuscular and intradermal vaccines versus intramuscular vaccine alone for elderly.
    Leung MK; You JH
    Vaccine; 2016 May; 34(22):2469-76. PubMed ID: 27079928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
    Yang MC; Tan EC; Su JJ
    Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic transmission modelling.
    Dawa J; Emukule GO; Barasa E; Widdowson MA; Anzala O; van Leeuwen E; Baguelin M; Chaves SS; Eggo RM
    BMC Med; 2020 Aug; 18(1):223. PubMed ID: 32814581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
    Rothberg MB; Rose DN
    Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
    Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
    Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of introducing national seasonal influenza vaccination for adults aged 60 years and above in mainland China: a modelling analysis.
    Yang J; Atkins KE; Feng L; Baguelin M; Wu P; Yan H; Lau EHY; Wu JT; Liu Y; Cowling BJ; Jit M; Yu H
    BMC Med; 2020 Apr; 18(1):90. PubMed ID: 32284056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults.
    Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Zimmerman RK
    J Am Geriatr Soc; 2016 Oct; 64(10):2126-2131. PubMed ID: 27709600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany.
    Scholz SM; Weidemann F; Damm O; Ultsch B; Greiner W; Wichmann O
    Value Health; 2021 Jan; 24(1):32-40. PubMed ID: 33431151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China.
    Jiang M; Li P; Wang W; Zhao M; Atif N; Zhu S; Fang Y
    Vaccine; 2020 Jan; 38(5):1057-1064. PubMed ID: 31787414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.